Description and Brand Names
Drug information provided by: IBM Micromedex
US Brand Name
- Danyelza
Descriptions
Naxitamab-gqgk injection is used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat relapsed (has come back) or refractory (did not respond to previous treatment) high-risk neuroblastoma (a type of cancer that most often occurs in young children) in the bone or bone marrow in patients who have shown a partial response, a minor response, or have stable disease to previous treatment. This medicine is a GD2-binding monoclonal antibody.
This medicine is to be given only by or under the direct supervision of your doctor.
This product is available in the following dosage forms:
Portions of this document last updated: Jan. 01, 2021
Copyright © 2021 IBM Watson Health. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.